What is ARA-290 / cibinetide, and does the nerve-repair peptide actually work?

The short answer

ARA-290, also known as cibinetide, is an 11-amino-acid peptide derived from erythropoietin (EPO) that activates the "innate repair receptor" to reduce inflammation and support nerve repair — without stimulating red blood cell production. Unusually for a gray-market peptide, it has real human trial data: in small-fiber neuropathy from sarcoidosis, a Phase 2b trial met its primary endpoint on nerve-fiber regeneration. But it's still investigational, not approved, and unproven for the general "recovery" use it's marketed for.

Evidence tier: Tier 1–2 for small-fiber neuropathy trials; Tier 3 (no evidence) for general anti-inflammatory/recovery use in healthy people. Educational content, not medical advice.

The key points:

• EPO-derived, but non-erythropoietic — the tissue-protective effect without EPO's clotting risk
• Real human trials in sarcoidosis small-fiber neuropathy — a Phase 2b met its endpoint
• Still investigational — not FDA-approved for anything
• No evidence for healthy "recovery/anti-inflammatory" use — that's extrapolation

For how we grade this kind of evidence, see peptide evidence grades.

What is ARA-290 (cibinetide)?

Evidence tier: 1–2 — well-characterized mechanism.

ARA-290 is a synthetic 11-amino-acid peptide built from the tissue-protective region of erythropoietin (EPO) — the hormone best known for stimulating red blood cell production. The clever design point is that ARA-290 was engineered to keep EPO's protective and anti-inflammatory actions while removing its red-blood-cell-stimulating effect. It does this by targeting a distinct receptor: the innate repair receptor (IRR), a heteromer that mediates tissue protection, rather than the classic EPO receptor that drives red-cell production. Developed by Araim Pharmaceuticals, it's also called cibinetide.

Why does that matter? EPO itself has tissue-protective and neuroprotective properties, but using EPO as a repair drug is dangerous because raising red blood cell mass increases clotting and cardiovascular risk. ARA-290 was designed to sidestep exactly that problem — protection and anti-inflammation without the hematologic hazard. Mechanistically, activating the IRR is thought to switch injured tissue from an inflammatory state toward repair, which is the basis for testing it in nerve damage and inflammatory conditions (Dahan et al., innate repair receptor review). So ARA-290 sits in a genuinely interesting scientific niche — but the important question is what it's actually been shown to do in people.

What is ARA-290 actually proven for?

Evidence tier: 1 — published human randomized trials.

Here's where ARA-290 stands apart from most gray-market peptides: it has real, published human trial data in a specific condition — small-fiber neuropathy (SFN) associated with sarcoidosis, a painful nerve disorder. An early randomized, double-blind, placebo-controlled pilot in sarcoidosis patients with SFN symptoms found ARA-290 safe and associated with symptom improvement (Heij et al. 2012, *Mol Med*). More convincingly, a Phase 2b trial in 64 patients with sarcoid-associated small-nerve-fiber loss and neuropathic pain — testing daily subcutaneous cibinetide against placebo for 28 days — met its pre-specified primary endpoint, showing increased corneal nerve fiber area (a marker of nerve regeneration) versus placebo (IOVS 2017).

That's a meaningful result: a controlled trial showing an objective, measurable sign of nerve repair, not just self-reported feelings. It's the kind of evidence most peptides in the gray market simply don't have. The honest qualifiers: these trials are in a specific disease (sarcoid neuropathy), the studies are relatively small and short, and even a positive Phase 2b is not a Phase 3 or an approval. ARA-290 has also been explored in diabetic small-fiber neuropathy and other inflammatory contexts. So the accurate statement is that ARA-290 has promising, genuine human evidence for a particular neuropathic condition — which is both more than the hype-peptides can claim and narrower than the marketing implies.

Does ARA-290 work for general "recovery" or inflammation in healthy people?

Evidence tier: 3 — no evidence for this use.

This is the gap between the science and the sales pitch. ARA-290 is marketed to biohackers broadly for "nerve repair," "anti-inflammatory recovery," injury healing, and even anti-aging — but the human evidence is in patients with a diagnosed neuropathic disease, not healthy people seeking general recovery or inflammation reduction. There is no trial showing ARA-290 improves recovery, performance, or well-being in people without a nerve disorder, and extrapolating "regenerates nerve fibers in sarcoid neuropathy" to "will help my training recovery / general inflammation" is a leap the data doesn't support.

The mechanism (shifting injured tissue toward repair) is plausible enough that broader uses are worth studying — but "plausible mechanism" is not "demonstrated benefit," and healthy tissue isn't in the injured, inflammatory state the drug is designed to act on. So the realistic read is that ARA-290 is a legitimately promising therapeutic for specific neuropathic conditions, being used speculatively and off-label by people for whom it hasn't been tested. That distinction — real drug, narrow evidence, broad marketing — is the recurring pattern across the peptide space, covered in longevity peptide stacks and the immune/gut peptides overview.

How does it compare to other anti-inflammatory peptides?

Evidence tier: 2 — comparative context.

ARA-290's relative strength is its human trial base. Many peptides marketed for inflammation and repair — BPC-157, TB-500, KPV, LL-37 — rest largely on animal or mechanistic data, whereas ARA-290 has controlled human trials (in a specific indication) behind it. Its non-erythropoietic design is also genuinely elegant, capturing a protective mechanism while avoiding EPO's dangerous hematologic effects. On the evidence ladder for its studied use, that puts it a notch above most gray-market anti-inflammatory peptides (LL-37 antimicrobial peptide guide for a contrasting mechanism).

But "better evidence than BPC-157 for neuropathy" is not the same as "proven for whatever you want to use it for." Two peptides can both be unproven for a given person's goal while differing in how much real research exists. ARA-290's advantage is specific and narrow: it's a serious investigational drug for neuropathic pain with positive controlled data — not a validated general-purpose recovery or anti-inflammatory agent. The comparison that matters isn't "which peptide is strongest" but "what has this peptide actually been shown to do, in whom" — and for ARA-290 the answer is nerve regeneration in sarcoid small-fiber neuropathy.

What are the risks and current status?

Evidence tier: 2 — safety data plus regulatory status.

On tolerability, ARA-290's trial safety profile has been relatively favorable — a key design goal was to avoid EPO's clotting and cardiovascular risks, and the studies didn't show the hematologic effects that make EPO hazardous. That's reassuring about the molecule as tested. But it says nothing about a random gray-market vial: the ARA-290 sold online is an unapproved research peptide with the usual authenticity, purity, dosing, and sterility risks of any self-sourced injectable (spotting counterfeit peptides), used for indications and in people it hasn't been tested in.

On status, ARA-290 is investigational and not approved anywhere as a marketed drug. Its most advanced evidence is Phase 2b in an orphan neuropathic condition; it has not completed the confirmatory trials or regulatory review that approval requires. So the honest framing is that ARA-290 is one of the more scientifically credible peptides for a specific neuropathic use — worth watching in real clinical development — but not an approved therapy, and certainly not a validated general recovery or anti-inflammatory booster to self-administer. If you have a diagnosed neuropathy, that's a conversation for a clinician and, ideally, a clinical trial — not a gray-market vial.

Limitations

This is educational content, not medical advice.

• Human evidence is specific to small-fiber neuropathy (sarcoidosis) — not general recovery or inflammation.
• Still investigational — no regulatory approval; most advanced data is Phase 2b.
• Trials are small/mid-size and short — promising, but not confirmatory.
• No evidence in healthy people — the broad "recovery/anti-inflammatory" marketing outruns the data.
• Gray-market ARA-290 carries authenticity, purity, and sterility risks; it isn't the trial product.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

ARA-290 (cibinetide) is a genuinely interesting peptide: an EPO-derived, non-erythropoietic activator of the innate repair receptor that reduces inflammation and supports nerve repair without EPO's clotting risk — and, unusually, it has real human trial data, including a Phase 2b that met its primary endpoint for nerve-fiber regeneration in sarcoidosis small-fiber neuropathy. That makes it more evidence-backed than most gray-market peptides for its studied use. But that use is narrow: the data are in a specific neuropathic disease, the trials are early-to-mid stage, it's not approved, and there's no evidence it helps general recovery or inflammation in healthy people. It's a credible investigational nerve-repair therapy to watch — not a proven all-purpose anti-inflammatory peptide to self-source.

Related on this site

• Peptide evidence grades explained
• Immune & gut peptides overview
• LL-37 antimicrobial peptide guide
• Longevity peptide stacks: what the evidence says
• Spotting counterfeit peptides
• Our evidence-tier framework

References

• Heij L, et al. 2012. Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study. Mol Med 18:1430–1436. PMID 23168581 — pilot RCT in sarcoid SFN.
• Culver DA, et al. 2017. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Invest Ophthalmol Vis Sci. doi:10.1167/iovs.16-21291 — Phase 2b, primary endpoint met.
• Dahan A, et al. 2016. Targeting the innate repair receptor to treat neuropathy. Pain Rep. PMC5741312 — IRR mechanism review.